Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US-2015368246-A1 · Dec 24, 2015 · US
US9227972B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9227972-B2 |
| Application number | US-201314399649-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 3, 2013 |
| Priority date | May 9, 2012 |
| Publication date | Jan 5, 2016 |
| Grant date | Jan 5, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Opening claim text (preview).
What is claimed is: 1. A compound which is: (3′S)-3-(3-(6-Methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,5-trifluorophenyl)piperidin-3-yl)prop-1-en-1-yl)-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridin]-2′(1′H)-one; or a pharmaceutically acceptable salt thereof. 2. A compound of the Formula: wherein, “nR A ” is from 0 to 4 halogen substituents and R B and R C are independently C 1-6 -alkyl which are optionally substituted with halogen. 3. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 4. A method of treating Migraine by providing an effective amount of a pharmaceutical formulation of claim 3 to a patient in need thereof.
Antimigraine agents · CPC title
having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine · CPC title
having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide · CPC title
containing further heterocyclic ring systems · CPC title
Spiro-condensed systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.